Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC0148-0287sema · 1 trial · 1 indication
Measured in pmol\*h/L for insulin 287 following administration of a fixed ratio of NNC0148-0287sema and insulin 287.
Measured in pmol\*h/L for semaglutide following administration of a fixed ratio of NNC0148-0287sema and semaglutide.
| Arm | Type | Description |
|---|---|---|
| Semaglutide plus insulin 287 | EXPERIMENTAL | Participants will get a single dose of fixed-ratio combination of insulin 287 and semaglutide (NNC0148-0287sema (treatment C)). |
| Semaglutide alone | EXPERIMENTAL | Participants will get a single dose of semaglutide (treatment B) alone. |
| Insulin 287 alone | EXPERIMENTAL | Participants will get a single dose of insulin 287 (NNC0148-0287 (treatment A)) alone. |
| Name | Type | Description |
|---|---|---|
| NNC0148-0287sema | DRUG | Study staff will inject NNC0148-0287sema, 175unit (U)/0.5 mg in the morning after fasting under the skin of participants' thigh using a needle and a pen. |
| Semaglutide | DRUG | Study staff will inject semaglutide, 0.5 mg alone in the morning after fasting under the skin of participants' thigh using a needle and a pen. |
| NNC0148-0287 | DRUG | Study staff will inject insulin 287 (NNC0148-0287), 175U alone in the morning after fasting under the skin of participants' thigh using a needle and a pen. |
Inclusion Criteria: * Male or female, aged 18-64 years (both inclusive) at the time of signing informed consent * Diagnosed with type 2 diabetes mellitus more than or equal to 180 days prior to the day of screening * Body weight between 80.0 to 120.0 kg (both inclusive) * Glycosylated haemoglobin (...
NNC0148-0287sema is an investigational small molecule being studied for the treatment of Type 2 Diabetes Mellitus. It is a metabolic therapeutic developed by Novo Nordisk A/S. As of now, it is in Phase 1 clinical development and has not been approved for any use.
NNC0148-0287sema is being developed by Novo Nordisk A/S, a pharmaceutical company listed on the stock exchange under the ticker NVO. The drug is currently in Phase 1 clinical trials for Type 2 Diabetes Mellitus.
NNC0148-0287sema is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied for the treatment of Type 2 Diabetes Mellitus.
NNC0148-0287sema has one completed clinical trial, identified as NCT03789578. This Phase 1 study, conducted in Germany, enrolled 30 participants and examined how the drug works in the body of people with Type 2 Diabetes when taken alone or together with insulin 287.
NNC0148-0287sema is a distinct investigational drug developed by Novo Nordisk. While its name includes 'sema', it is not stated to be the same as semaglutide. The drug is being studied for Type 2 Diabetes Mellitus and is currently in Phase 1 clinical trials.